Prognostic Value of SII and SIRI in Obesity-Related Metabolic Complications

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Rijeka

About this trial

This observational study aims to evaluate the diagnostic and prognostic value of the systemic immune-inflammatory index (SII) and the systemic inflammation response index (SIRI) in individuals with overweight or obesity. The study will assess their association with obesity status, metabolic complications, lifestyle patterns, dietary indices, and established inflammatory biomarkers. Participants will undergo anthropometric assessment, laboratory testing, dietary evaluation, and follow-up for response to different obesity treatment modalities over 3 years. The study intends to determine whether SII and SIRI can serve as clinically useful predictors of metabolic risk and treatment outcomes of obesity.

Eligibility criteria

Qualifiers

Age ≥ 18 years

BMI 25.0-29.9 kg/m² (overweight) or BMI ≥ 30 kg/m² (obesity)

Ability to attend scheduled clinical visits

Willingness to provide informed consent

Disqualifiers

Pregnancy or breastfeeding

Use of immunosuppressive therapy

Active infection

Inflammatory disease

Trial design

Treatments tested in this trial

  • Nutritional counselling

Treatment groups

200 Participants
are divided into 1 treatment group

Sponsors and collaborators